Most recently, the FIDELIO-DKD trial reported that MR antagonism, with finerenone, lowered the risk of CKD progression, reduced albuminuria, and reduced cardiovascular events in patients with CKD and type 2 diabetes, further highlighting the utility of MR antagonists in clinical practice (13). This evidence concerns the gene NR3C2 and chronic kidney disease.